Syenza’s News Roundup: Launching a New Era of Healthcare Insights

By HEOR Staff Writer

September 7, 2023

We are excited to announce the launch of our new newsletter, “Value Science Weekly”. This weekly digest is designed to keep you up-to-date on the latest trends, insights, and breakthroughs in Health Economics and Outcomes Research (HEOR), Global Market Access, and Dynamic Intelligence.

In our next week’s issue, we delve into the transformative potential of virtual care in neurology, as highlighted by the World Health Organization. The rising demand for continuous home and institutional care, driven by an ageing population and increasing prevalence of chronic diseases, is being met head-on by advancements in virtual care. Our rapid insight article explores how virtual care is reshaping patient evaluation, treatment, and follow-up, particularly in the field of neurology.

But that’s just the beginning. Each week, our newsletter will bring you expert perspectives and thought-provoking analyses from renowned researchers and industry leaders. You’ll also discover the latest studies and real-world evidence shaping the economic value and patient outcomes of healthcare interventions. Plus, we’ll keep you informed about policy changes, regulatory updates, and reimbursement frameworks that could impact your work.

We’re also excited to share innovations in market access and healthcare delivery, showcasing the cutting-edge technologies and transformative approaches that are emerging in our industry.

Don’t miss out on these valuable insights. Subscribe to “Value Science Weekly” today for your weekly dose of healthcare innovation news. We look forward to embarking on this journey with you.

Reference url

Recent Posts

FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Adverse Drug Reporting

By João L. Carapinha

March 11, 2026

The U.S. Food and Drug Administration (FDA) issued the FDA Warning Letter Novo Nordisk dated March 5, 2026, to Novo Nordisk Inc. (NNI)...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review

By João L. Carapinha

March 10, 2026

Economic evaluations of vaccines targeting multi-disease combinations, such as hepatitis A/B or measles-mumps-rubella (MMR), reveal critical methodological shortcomings in this systematic literature review. Synthesiz...
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo, has received P...